keyword
MENU ▼
Read by QxMD icon Read
search

NSCLC

keyword
https://www.readbyqxmd.com/read/29156837/meta-analysis-of-efficacy-and-adverse-events-of-erlotinib-based-targeted-therapies-for-advanced-metastatic-non-small-cell-lung-cancer
#1
Fei Li, Shu-Hua Zhang, Li-Min Pang
A network meta-analysis evaluating efficacy and adverse events of eight erlotinib-based therapies (erlotinib+placebo, erlotinib+tivantinib, erlotinib+celecoxib, erlotinib+onartuzumab, erlotinib+sunitinib, erlotinib+entinostat, erlotinib+sorafenib, and erlotinib+bevacizumab) for advanced/metastatic non-small-cell lung cancer (NSCLC) was performed. PubMed and Cochrane Library were reviewed, and ten randomized controlled trials were identified in which patients receiving at least one erlotinib-based therapy. Efficacy outcomes, including progression-free survival (PFS), overall survival (OS), overall response rate (ORR), disease control rate (DCR), and adverse outcomes were evaluated...
October 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/29156821/prognostic-significance-of-circulating-tumor-cells-in-non-small-cell-lung-cancer-patients-undergoing-chemotherapy
#2
Bing Tong, Yan Xu, Jing Zhao, Minjiang Chen, Jia Xing, Wei Zhong, Mengzhao Wang
The utility of circulating tumor cells (CTCs) as prognostic biomarkers in non-small cell lung cancer (NSCLC) is inconclusive due to the limitations of current CTC detection methods. Using a novel high-efficiency detection method, we determined the ability of CTCs to predict survival and chemotherapeutic responses in NSCLC. In 127 patients with advanced NSCLC, CTCs were counted and analyzed at baseline and during follow-up. Median overall survival (OS) and progression-free survival (PFS) were longer in patients with baseline CTC counts <8 CTCs/3...
October 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/29156777/patients-with-nsclc-may-display-a-low-ratio-of-p-t790m-vs-activating-egfr-mutations-in-plasma-at-disease-progression-implications-for-personalised-treatment
#3
Marzia Del Re, Paola Bordi, Iacopo Petrini, Eleonora Rofi, Francesca Mazzoni, Lorenzo Belluomini, Enrico Vasile, Giuliana Restante, Francesco Di Costanzo, Alfredo Falcone, Antonio Frassoldati, Ron H N van Schaik, Christi M J Steendam, Antonio Chella, Marcello Tiseo, Riccardo Morganti, Romano Danesi
Introduction: NSCLC harboring activating mutations of EGFR is highly sensitive to first-line EGFR-tyrosine kinase inhibitors (TKIs), but drug resistance depending on the EGFR mutation p.T790M will occur in about 50-60% of patients. Detailed information on the amount of p.T790M plasmatic level associated with resistance to EGFR-TKIs and guidance to treatment with p.T790M-effective TKI depending on these levels, is lacking. Methods: This study enrolled p.T790M-positive patients (n=49) affected by EGFR-mutated NSCLC at progression to first-line EGFR-TKIs and, in selected cases (n=5), after second-line treatment with osimertinib...
October 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/29156644/akt1-stimulates-homologous-recombination-repair-of-dna-double-strand-breaks-in-a-rad51-dependent-manner
#4
Katharina Mueck, Simone Rebholz, Mozhgan Dehghan Harati, H Peter Rodemann, Mahmoud Toulany
Akt1 is known to promote non-homologous end-joining (NHEJ)-mediated DNA double-strand break (DSB) repair by stimulation of DNA-PKcs. In the present study, we investigated the effect of Akt1 on homologous recombination (HR)-dependent repair of radiation-induced DSBs in non-small cell lung cancer (NSCLC) cells A549 and H460. Akt1-knockdown (Akt1-KD) significantly reduced Rad51 protein level, Rad51 foci formation and its colocalization with γH2AX foci after irradiation. Moreover, Akt1-KD decreased clonogenicity after treatment with Mitomycin C and HR repair, as tested by an HR-reporter assay...
November 20, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29156520/long-noncoding-rna-linc00961-inhibits-cell-invasion-and-metastasis-in-human-non-small-cell-lung-cancer
#5
Bin Jiang, Jing Liu, Yu-Hong Zhang, Dong Shen, Shaoping Liu, Feng Lin, Jun Su, Qing-Feng Lin, Shuai Yan, Yong Li, Wei-Dong Mao, Zhi-Li Liu
Long noncoding RNAs (LncRNAs) expression has been found to be misregulated in multiple human cancers, and a growing number of studies have revealed that lncRNAs can function as important oncogenes or tumor suppressors. In this study, we identified a lncRNA-LINC00961, which was significantly down-regulated in human non-small cell lung cancer tissues. Decreased LINC00961 was associated with NSCLC patients advanced clinical stage, lymph node metastasis, and shorter survival time. Further experiments demonstrated that LSD1 could directly bind to LINC00961 promoter regions and epigenetically repress its transcription in NSCLC cells...
November 14, 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/29156517/mir-504-inhibits-cell-proliferation-and-invasion-by-targeting-loxl2-in-non-small-cell-lung-cancer
#6
Ming-Fan Ye, Ji-Guang Zhang, Tian-Xing Guo, Xiao-Jie Pan
BACKGROUND: MicroRNAs (miRNAs) play crucial roles in tumor initiation and development. The aim of the study was to explore the clinicopathological role and functional effects of miR-504 in non small cell lung cancer (NSCLC). METHODS: Quantitative reverse transcription polymerase chain reaction (QRT-PCR) was applied to detect the expression of miR-504 in 55 cases of NSCLC tissues and matched adjacent normal tissues in NSCLC patients. MTT, colony formation and transwell invasion assays were performed to evaluate the effects of miR-504 on cell proliferation and invasion, respectively...
November 14, 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/29156447/pd-1-blockade-in-advanced-nsclc-a-focus-on-pembrolizumab
#7
REVIEW
Solange Peters, Keith M Kerr, Rolf Stahel
Non-small cell lung cancer (NSCLC) is one of the most prevalent cancers and is responsible for a large proportion of all cancer-related deaths. Current treatment options are inadequate, reflecting a substantial unmet clinical need. Increasing knowledge regarding the mechanisms and genetic aberrations underlying tumor development and growth has heralded a new era of therapy in oncology, moving away from indiscriminate cytotoxic chemotherapy toward more finely focused, targeted medicine. The development of small-molecule drugs and monoclonal antibodies directed toward specific components of dysfunctional molecular or immune pathways, and mutated genes specific to particular cancer types, is leading the field to more personalized and less toxic treatment options, many of which have demonstrated greater efficacy and survival benefits than their chemotherapeutic counterparts...
October 23, 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29154817/cancer-stem-cell-like-population-is-preferentially-suppressed-by-egfr-tkis-in-egfr-mutated-pc-9-tumor-models
#8
Fan Yang, Yang Li, Bin Liu, Jiacong You, Qinghua Zhou
AIMS: Although the epidermal growth factor receptor (EGFR) and Wnt/β-catenin signaling systems synergistically regulate many essential developmental and regenerative processes in lung cancer, the mechanisms of their crosstalk remain poorly defined. Our study aimed to investigate an interaction between EGFR and the β-catenin signal. RESULTS: In this study, we described a potent activation of β-catenin by EGFR, which is dependent of the PtdIns3K/AKT pathway. We found EGF activated β-catenin signaling via phosphorylation of EGFR and AKT in EGFR-mutated PC-9 lung cancer cells...
November 14, 2017: Experimental Cell Research
https://www.readbyqxmd.com/read/29153966/nomogram-to-predict-cause-specific-mortality-in-patients-with-surgically-resected-stage-i-non-small-cell-lung-cancer-a-competing-risk-analysis
#9
Huaqiang Zhou, Yaxiong Zhang, Zeting Qiu, Gang Chen, Shaodong Hong, Xi Chen, Zhonghan Zhang, Yan Huang, Li Zhang
BACKGROUND: The objective of this study was to evaluate the probability of cause-specific death and other causes of death in patients with stage I non-small-cell lung cancer (NSCLC) who underwent surgery. We also built competing risk nomograms to predict the prognosis of patients with NSCLC. PATIENTS AND METHODS: Data were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. We identified patients who underwent surgery with stage I NSCLC between 2004 and 2013...
October 28, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29153898/the-significance-of-the-pd-l1-expression-in-non-small-cell-lung-cancer-trenchant-double-swords-as-predictive-and-prognostic-markers
#10
REVIEW
Kazuki Takada, Gouji Toyokawa, Fumihiro Shoji, Tatsuro Okamoto, Yoshihiko Maehara
Lung cancer is the leading cause of death due to cancer worldwide. Surgery, chemotherapy, and radiotherapy have been the standard treatment for lung cancer, and targeted molecular therapy has greatly improved the clinical course of patients with non-small-cell lung cancer (NSCLC) harboring driver mutations, such as in epidermal growth factor receptor and anaplastic lymphoma kinase genes. Despite advances in such therapies, the prognosis of patients with NSCLC without driver oncogene mutations remains poor. Immunotherapy targeting programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) has recently been shown to improve the survival in advanced NSCLC...
October 28, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29153897/comparison-of-single-and-three-fraction-schedules-of-stereotactic-body-radiation-therapy-for-peripheral-early-stage-non-small-cell-lung-cancer
#11
Sung Jun Ma, Lucas M Serra, Yusef A Syed, Gregory M Hermann, Jorge A Gomez-Suescun, Anurag K Singh
BACKGROUND: To compare the clinical outcomes of patients with early-stage non-small-cell lung cancer (NSCLC) who had undergone either single-fraction (SF) or three-fraction (TF) stereotactic body radiation therapy (SBRT) at a single institution during over 8-year period. PATIENTS AND METHODS: Patients with peripherally located early-stage NSCLC who had undergone SBRT from February 2007 to November 2015 were included in the present study. SBRT was delivered without heterogeneity correction...
October 28, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29153896/sequential-ct-findings-in-patients-with-non-small-cell-lung-cancer-receiving-nivolumab
#12
David Y Johnson, Ryan G Short, Edward F Patz
BACKGROUND: Nivolumab is a novel immunotherapy that was recently approved for treatment of advanced non-small-cell lung cancer (NSCLC). Patients treated with checkpoint inhibitors may show variable computed tomography (CT) features on follow-up imaging, and it is unclear how reliable conventional response criteria are to determine patient management and outcomes. We report the spectrum of sequential CT findings in patients with advanced stage lung cancer who received nivolumab in an effort to better inform appropriate imaging strategies...
October 28, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29153372/impact-of-experimental-design-on-pet-radiomics-in-predicting-somatic-mutation-status
#13
Stephen S F Yip, Chintan Parmar, John Kim, Elizabeth Huynh, Raymond H Mak, Hugo J W L Aerts
PURPOSE: PET-based radiomic features have demonstrated great promises in predicting genetic data. However, various experimental parameters can influence the feature extraction pipeline, and hence, Here, we investigated how experimental settings affect the performance of radiomic features in predicting somatic mutation status in non-small cell lung cancer (NSCLC) patients. METHODS: 348 NSCLC patients with somatic mutation testing and diagnostic PET images were included in our analysis...
December 2017: European Journal of Radiology
https://www.readbyqxmd.com/read/29152741/neat1-acts-as-an-inducer-of-cancer-stem-cell-like-phenotypes-in-nsclc-by-inhibiting-egcg-upregulated-ctr1
#14
Pan Jiang, Aochang Chen, Xiaoyue Wu, Ming Zhou, Ijaz Ul Haq, Zahula Mariyam, Qing Feng
Long non-coding RNAs (lncRNAs) play significant roles in the pathogenesis of various cancers, including lung cancer. In this study, we aimed to investigate the biological function of lncRNA nuclear enriched abundant transcript 1 (NEAT1) in cancer stem cells (CSCs). CSCs have been suggested as the main cause of tumor metastasis, tumor recurrence and chemotherapy resistance. The copper transporter 1 (CTR1) has been the focus of many recent studies because of its correlation with cisplatin (CDDP) resistance. So far, the mechanism of how NEAT1 regulates CSCs in NSCLC remains unknown...
November 19, 2017: Journal of Cellular Physiology
https://www.readbyqxmd.com/read/29152147/microrna-370-inhibits-the-growth-and-metastasis-of-lung-cancer-by-down-regulating-epidermal-growth-factor-receptor-expression
#15
Xin Liu, You-Guang Huang, Cong-Guo Jin, Yong-Chun Zhou, Xiao-Qun Chen, Jia Li, Yan Chen, Mei Li, Qian Yao, Ke Li, Min Lan, Jia-Gui Ye, Xi-Cai Wang
Abnormal microRNA-370 (miR-370) expression has been frequently reported in several types of cancers, including lung cancer. However, the role and molecular mechanisms of miR-370 in regulating the growth and metastasis of lung cancer have not been clarified. Here, we show higher levels of epidermal growth factor receptor (EGFR), but lower levels of miR-370 expression in most human lung cancer cells and non-tumor cells. Induction of miR-370 over-expression significantly reduced the levels of EGFR expression and the EGFR 3'untranslated region (UTR)-regulated luciferase activity in XWLC-05 and H157 cells, suggesting that miR-370 may bind to the 3'UTR of EGFR mRNA...
October 20, 2017: Oncotarget
https://www.readbyqxmd.com/read/29152093/the-role-of-weekly-nanoparticle-albumin-bound-paclitaxel-monotherapy-as-second-line-or-later-treatment-for-advanced-nsclc-in-china
#16
Puyuan Xing, Yixiang Zhu, Ling Shan, Sipeng Chen, Xuezhi Hao, Junling Li
For patients with pretreated advanced non-small cell lung cancer (NSCLC), more effective treatments are unmet. We conducted a study to explore the optimal treatment schedule of nanoparticle albumin bound paclitaxel (Nab-PTX) as a second line or later treatment for advanced NSCLC patients in China. Ninety-eight patients, who had experienced failure of prior treatment and received Nab-PTX monotherapy (130 mg/m(2)) on days 1, 8 of a 21-day cycle were included. The median progression-free survival (PFS) and overall survival (OS) were 4...
October 20, 2017: Oncotarget
https://www.readbyqxmd.com/read/29152079/an-analysis-of-the-gene-interaction-networks-identifying-the-role-of-parp1-in-metastasis-of-non-small-cell-lung-cancer
#17
Kai Chen, Yajie Li, Hui Xu, Chunfeng Zhang, Zhiqiang Li, Wei Wang, Baofeng Wang
Background and Objective: Though there were many researches about the effects of cancer cells on non-small cell lung cancer (NSCLC) currently, it has been rarely reported completed oncogene and its mechanism in tumors by far. Here, we used biological methods with known oncogene of NSCLC to find new oncogene and explore its functionary mechanism in NSCLC. Methods: The study firstly built NSCLC genetic interaction network based on bioinformatics methods and then combined shortest path algorithm with significance test to confirmed core genes that were closely involved with given genes; real-time qPCR was conducted to detect expression levels between patients with NSCLC and normal people; additionally, detection of PARP1's role in migration and invasion was performed by trans-well assays and wound-healing...
October 20, 2017: Oncotarget
https://www.readbyqxmd.com/read/29152077/concordance-of-programmed-death-ligand-1-expression-between-primary-and-metastatic-non-small-cell-lung-cancer-by-immunohistochemistry-and-rna-in-situ-hybridization
#18
Hye Ryun Kim, Yoon Jin Cha, Min Hee Hong, Manoj Gandhi, Shauna Levinson, Inkyung Jung, Jin Gu Lee, Chang Young Lee, Byoung Chul Cho, Sang-Jun Ha, Hyo Sup Shim
We investigated the concordance of programmed death-ligand 1 (PD-L1) expression between primary cancer at initial diagnosis and metastasis at recurrence in resected non-small cell lung cancer (NSCLC). PD-L1 expression was evaluated using the SP142 assay in 37 NSCLC patients with paired primary lung cancer and surgically resected metastases at recurrence. PD-L1 positivity was defined as immunohistochemistry (IHC) and also evaluated by RNA in situ hybridization (RISH). The concordance rate of PD-L1 between primaries and metastases and correlation with clinicopathological factors were analyzed...
October 20, 2017: Oncotarget
https://www.readbyqxmd.com/read/29152062/rapamycin-sensitizes-cancer-cells-to-growth-inhibition-by-the-parp-inhibitor-olaparib
#19
Atsushi Osoegawa, Joell J Gills, Shigeru Kawabata, Phillip A Dennis
Poly (ADP-ribose) polymerase inhibitors (PARPi) have been developed and tested in a context of combining it with double-stranded (ds) DNA repair defects or inhibitors, as PARP inhibitor impairs single-stranded (ss) DNA break repair, resulting in the activation of the dsDNA break repair machinery. Rapamycin has been widely prescribed for more than a decade and recent studies have revealed that it may inhibit dsDNA break repair. The combination of the PARP inhibitor olaparib and rapamycin synergistically inhibited cell proliferation in non-small cell lung cancer (NSCLC) cells, and even in triple negative breast cancer (TNBC) cells with BRCA1 mutations...
October 20, 2017: Oncotarget
https://www.readbyqxmd.com/read/29151973/roles-of-micrornas-in-the-resistance-to-platinum-based-chemotherapy-in-the-non-small-cell-lung-cancer
#20
REVIEW
Hongjing Zang, Jianlun Peng, Weiyuan Wang, Songqing Fan
Platinum-based adjuvant chemotherapy improves survival among patients with lung tumors, in particular non-small cell lung cancer (NSCLC). But the predicament of drug resistance in NSCLC patients is frustrating us. The profiles of microRNAs are different between platinum chemotherapy resistant and sensitive NSCLC cells. Researches regarding microRNAs and their targets, in platinum drug resistant cases, illuminate novel ideals for platinum-based chemotherapy for NSCLC patients. Therefore, in this review we will focus on three aspects: Epithelial-mesenchymal transition (EMT), cell proliferation and apoptosis, and the roles of microRNAs in cisplatin (CDDP) and carboplatin (CBP) resistance...
2017: Journal of Cancer
keyword
keyword
258
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"